Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 17/20 | 0.63 |
| ▸ | RARG | P13631 | 15/20 | 0.63 |
| ▸ | RARA | P10276 | 15/20 | 0.63 |
| ▸ | RXRA | P19793 | 1/20 | 0.63 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6259669 | 0.94 | RARB (0.63) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL6262562 | 0.92 | RARA (0.75) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL6259689 | 0.90 | RARB (0.65) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL6259688 | 0.90 | RARB (0.65) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL6428466 | 0.88 | RARB (0.48) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL6261096 | 0.87 | RARB (0.47) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL6238262 | 0.87 | RARB (0.83) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL6238257 | 0.87 | RARB (0.83) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL6262565 | 0.86 | RARA (0.72) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL6428468 | 0.86 | RARB (0.51) | RARBRARGRARARXRANR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1185277-B1 | Use of FXR synthetic ligands for the treatment of diseseas linked to cholesterol imbalance and colon cancer | ALLERGAN INC (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6906057-B1 | Methods for modulating FXR receptor activity | ALLERGAN, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1185539-B1 | ORGANOSILYL COMPOUNDS HAVING NUCLEAR HORMONE RECEPTOR MODULATING ACTIVITY | ALLERGAN INC (US) | 2004-12-01 | — | — | EP | disclosed |
| US-6452032-B1 | ANTAGONISTS, AGONISTS, OR INVERSE AGONISTS PARTICULARLY FOR RETINOID AND FARNESOID RECEPTORS; REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION AND OF LIPID METABOLISM; DERMATOSES SUCH AS ACNE, PSORIASIS, ICTHYOSIS AND ECZEMA | ALLERGAN SALES, LLC | 2002-09-17 | — | — | US | disclosed |
| EP-1185539-A1 | ORGANOSILYL COMPOUNDS HAVING NUCLEAR HORMONE RECEPTOR MODULATING ACTIVITY | Allergan Sales, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000077011-A1 | ORGANOSILYL COMPOUNDS HAVING NUCLEAR HORMONE RECEPTOR MODULATING ACTIVITY | ALLERGAN SALES, INC. (US) | 2000-12-21 | — | — | WO | disclosed |